NCT00032110View on ClinicalTrials.gov

Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Adenocarcinoma of the ColonAdenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal Cancer
Interventions
DRUG

erlotinib hydrochloride

Given orally

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital Phase 2 Consortium, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00032110 - Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter